Nanoviricides Inc (NNVC)
1.10
-0.08
(-6.38%)
USD |
NYAM |
Apr 19, 16:00
1.10
0.00 (0.00%)
After-Hours: 20:00
Nanoviricides Research and Development Expense (Quarterly): 1.574M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.574M |
| September 30, 2023 | 1.467M |
| June 30, 2023 | 2.913M |
| March 31, 2023 | 1.196M |
| December 31, 2022 | 1.171M |
| September 30, 2022 | 1.113M |
| June 30, 2022 | 1.172M |
| March 31, 2022 | 1.255M |
| December 31, 2021 | 1.261M |
| September 30, 2021 | 2.097M |
| June 30, 2021 | 1.584M |
| March 31, 2021 | 1.464M |
| December 31, 2020 | 1.493M |
| September 30, 2020 | 1.573M |
| June 30, 2020 | 1.067M |
| March 31, 2020 | 1.134M |
| December 31, 2019 | 1.012M |
| September 30, 2019 | 1.482M |
| June 30, 2019 | 1.587M |
| March 31, 2019 | 1.310M |
| December 31, 2018 | 1.658M |
| September 30, 2018 | 1.412M |
| June 30, 2018 | 1.531M |
| March 31, 2018 | 1.291M |
| December 31, 2017 | 1.640M |
| Date | Value |
|---|---|
| September 30, 2017 | 1.452M |
| June 30, 2017 | 2.294M |
| March 31, 2017 | 1.559M |
| December 31, 2016 | 1.261M |
| September 30, 2016 | 1.452M |
| June 30, 2016 | 1.602M |
| March 31, 2016 | 1.068M |
| December 31, 2015 | 1.152M |
| September 30, 2015 | 1.282M |
| June 30, 2015 | 1.386M |
| March 31, 2015 | 0.5465M |
| December 31, 2014 | 0.9167M |
| September 30, 2014 | 0.8111M |
| June 30, 2014 | 2.201M |
| March 31, 2014 | 0.6257M |
| December 31, 2013 | 1.130M |
| September 30, 2013 | 1.174M |
| June 30, 2013 | 1.014M |
| March 31, 2013 | 1.359M |
| December 31, 2012 | 0.7102M |
| September 30, 2012 | 1.210M |
| June 30, 2012 | 1.013M |
| March 31, 2012 | 1.583M |
| December 31, 2011 | 1.012M |
| September 30, 2011 | 0.6917M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.012M
Minimum
Dec 2019
2.913M
Maximum
Jun 2023
1.453M
Average
1.464M
Median
Mar 2021
Research and Development Expense (Quarterly) Benchmarks
| Gilead Sciences Inc | 1.408B |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 5.554M |
| iBio Inc | 1.535M |
| Theriva Biologics Inc | 4.196M |